These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 39192322)

  • 81. Gene amplification in ductal carcinoma in situ of the breast.
    Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
    Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Assessment of treatment for patients with primary ductal carcinoma in situ in the breast.
    Fish EB; Chapman JA; Miller NA; Link MA; Fishell E; Wright B; McCready DR; Hiraki GY; Ross TM; Hanna WM; Lickley HL
    Ann Surg Oncol; 1998 Dec; 5(8):724-32. PubMed ID: 9869520
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
    Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Genomic Assays in Ductal Carcinoma In Situ: Implications for Management Decisions.
    Gangi A; Topham A; Lee MC; Sun W; Laronga C
    South Med J; 2017 Oct; 110(10):649-653. PubMed ID: 28973706
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
    Ubago JM; Blanco LZ; Shen T; Siziopikou KP
    Am J Clin Pathol; 2019 Jul; 152(2):169-176. PubMed ID: 30984969
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
    Ringberg A; Anagnostaki L; Anderson H; Idvall I; Fernö M;
    Eur J Cancer; 2001 Aug; 37(12):1514-22. PubMed ID: 11506959
    [TBL] [Abstract][Full Text] [Related]  

  • 89. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy.
    Noh JM; Lee J; Choi DH; Cho EY; Huh SJ; Park W; Nam SJ; Lee JE; Kil WH
    Breast; 2013 Oct; 22(5):894-7. PubMed ID: 23643805
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.
    Miligy IM; Toss MS; Shiino S; Oni G; Syed BM; Khout H; Tan QT; Green AR; Macmillan RD; Robertson JFR; Rakha EA
    Br J Cancer; 2020 Nov; 123(10):1513-1520. PubMed ID: 32773767
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ.
    Al Mushawah F; Rastelli A; Pluard T; Margenthaler JA
    J Surg Res; 2012 Mar; 173(1):10-5. PubMed ID: 21696764
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast.
    Tumedei MM; Silvestrini R; Ravaioli S; Massa I; Maltoni R; Rocca A; Folli S; Buggi F; Curcio A; Serra L; Puccetti M; Amadori D; Bravaccini S
    Int J Biol Markers; 2015 Nov; 30(4):e425-8. PubMed ID: 26165687
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ductal carcinoma in situ: a disease entity that merits more recognition.
    Dereere E; Papadimitriou K; Tjalma W; Altintas S
    Minerva Chir; 2015 Aug; 70(4):231-9. PubMed ID: 25916193
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.
    Toss M; Miligy I; Gorringe K; Mittal K; Aneja R; Ellis I; Green A; Rakha E
    J Clin Pathol; 2020 Feb; 73(2):76-82. PubMed ID: 31444238
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
    Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
    Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Overall survival is improved when DCIS accompanies invasive breast cancer.
    Kole AJ; Park HS; Johnson SB; Kelly JR; Moran MS; Patel AA
    Sci Rep; 2019 Jul; 9(1):9934. PubMed ID: 31289308
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS).
    Farnie G; Johnson RL; Williams KE; Clarke RB; Bundred NJ
    Cell Cycle; 2014; 13(3):418-25. PubMed ID: 24247151
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.
    Paszat L; Sutradhar R; Zhou L; Nofech-Mozes S; Rakovitch E
    Clin Breast Cancer; 2019 Feb; 19(1):35-46. PubMed ID: 30190195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.